89bio
ISIN US2825591033
|WKN A2PUP8
Market cap (in EUR)
949.37 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.
Healthcare Biopharmaceuticals Other Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 949.37 m |
| EPS, EUR | -3.17 |
| P/B ratio | 2.21 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 0.00 m |
| Net income, EUR | -339.36 m |
| Profit margin | - |
What ETF is 89bio in?
There are 15 ETFs which contain 89bio. All of these ETFs are listed in the table below. The ETF with the largest weighting of 89bio is the Harbor Health Care UCITS ETF Accumulating.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
